Overview

A Study of sEphB4-HSA in Kaposi Sarcoma

Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
sEphB-HSA may prevent tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor. The purpose of this study is to learn if sEphB4-HSA will decrease the number or size of Kaposi sarcoma lesions in people.
Phase:
Phase 2
Details
Lead Sponsor:
Vasgene Therapeutics, Inc